Portal Vein Thrombosis Treatment Guidelines

Indications for Anticoagulation

The American Association for the Study of Liver Diseases (AASLD) recommends anticoagulation for symptomatic portal vein thrombosis (PVT) for a minimum of 6 months to prevent thrombus extension and bowel ischemia 1, 2
Anticoagulation is indicated for acute complete or partial main portal vein occlusion, recent thrombosis (less than 6 months) that is completely or partially occlusive (>50%) of the main portal vein trunk 1, 3, 4
The AASLD recommends anticoagulation for liver transplant candidates with PVT unless they are actively bleeding 1, 4, 5

For patients with Child-Pugh A or B cirrhosis, either direct oral anticoagulants (DOACs) or low molecular weight heparin (LMWH) with or without vitamin K antagonists (VKAs) are acceptable options 1, 5
The Baveno Faculty endorses LMWH, VKA, and DOACs for patients with Child-Pugh A or B cirrhosis 1, 3

The AASLD recommends a minimum of 6 months of anticoagulation for all patients with symptomatic or progressive PVT 1, 3
Anticoagulation should be continued until transplantation for liver transplant candidates 1, 4

The AASLD recommends evaluating for the presence of varices and ensuring adequate management prior to initiating anticoagulant therapy 1, 6, 7
Patients should be screened for esophageal varices before starting anticoagulation 8

Imaging should be performed every 3 months to assess treatment response 8
Recanalization can be expected to occur up to 6 months after starting treatment 8

The AASLD recommends considering transjugular intrahepatic portosystemic shunt (TIPS) for liver transplant candidates with progressive PVT not responding to anticoagulation 2, 8

Overall bleeding complications with anticoagulation occur in approximately 5-14% of patients 8
Risk factors for bleeding include history of variceal bleeding, low serum albumin, and platelet count less than 50×10⁹/L 8

The American Society of Hematology recommends assessing platelet count before initiating anticoagulation, and anticoagulation should not be withheld for moderate thrombocytopenia, but requires case-by-case evaluation when platelets <50 × 10⁹/L 9
For patients with Child-Pugh A or B cirrhosis, either DOACs or LMWH with/without VKA are acceptable based on patient preference, with DOACs showing lower major bleeding risk compared to warfarin (HR 0.69; 95% CI 0.57-0.84) 9
Apixaban reduces recurrent VTE risk versus warfarin (HR 0.47; 95% CI 0.26-0.86) and demonstrates favorable safety (HR 0.43; 95% CI 0.30-0.63) 9

For patients with Child-Pugh C cirrhosis, LMWH alone should be used (or as bridge to VKA in patients with normal baseline INR), and DOACs should be avoided due to limited safety data 9
When platelet count is <50 × 10⁹/L, evaluate thrombus site, extent, and risk of extension, and consider full-dose anticoagulation if platelets >40-50 × 10⁹/L 9
Reduced-dose anticoagulation may be considered if platelets >25 × 10⁹/L beyond 30 days, particularly for limited thrombus burden 9